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thesis was not effective. However, the inhibition on penetration
was observed so effective that it can block HSV penetration
completely at the concentration of 0.736μg/ml.
Conclusion: We found that notoginsenoside ST-4 inhibited HSV
infection by blocking the viral penetration. Nowdays in the
absence of HSV vaccines and the emergence of drug-resistant
viruses, notoginsenoside ST-4 represents an important potential
strategy for treatments of HSV infection, especially preventing
the sexual spread of HSV-2.
OL-023 Activation of canonical Wnt signaling pathway
promotes proliferation and self-renewal of rat
hepatic oval cell line WB-F344 in vitro
Ying Zhang*, Fu-kui Zhang, Bao-en Wang. Liver Research Center,
Beijing Friendship Hospital, Beijing, China
Aim: To investigate the effect of activation of canonical Wnt
signaling pathway on the proliferation and differentiation of rat
heaptic oval cells in vitro.
Methods: WB-F344 cells were treated with recombinant wnt3a
(20, 40, 80, 160, 200 ng/ml) in the serum-free medium for 24
hours. Cell proliferation was measured by Brdu incorporation
analysis, un-treated WB-F344 cells were taken as control. After
treatment with Wnt3a (160ng/ml) for 24 hours, the subcellu-
lar localization and protein expression of β-catenin in Wnt3a
treated and untreated WB-F344 cells were examined by Im-
munoﬂuorescence Staining and Western-blot analysis. CyclinD1
mRNA expression was determined by semi-quantitative RT-PCR;
The mRNA levels of some phenotypic markers, including AFP,
CK-19,ALB, and two hepatic nuclear factors, HNF-4, HNF-6 were
determined by RT-PCR. CK-19 and AFP protein expression were
examined by Western-blot analysis.
Results: We found that Wnt3a promoted proliferation of WB-
F344 cells. Stimulation of WB-F344 cells with recombinant Wnt3a
resulted in the accumulation of the transcriptional activator
β-catenin, together with its translocation into the nucleus, and
the upregulation of typical Wnt target genes cyclin D1 After 3
days of Wnt3a treatment in the absence of any serum, these
cells retained their bipotential to express several speciﬁc hepa-
tocyte and cholangiocyte phenotypic markers, such as AFP, CK-19
following activation of canonical Wnt signaling pathway.
Conclusion: The canonical Wnt signaling pathway promotes pro-
liferation and self-renewal of rat hepatic oval cells.
OL-024 vfr: A novel locus affecting cysteine protease
production in Streptococcus pyogenes
Yongsheng Ma*,1,2, Amy Bryant2, Dennis Stevens2. 1Idaho State
University; 2VA Medical Center, USA
Background: Group A streptococcus (GAS) causes many hu-
man diseases ranging in severity from milder infections such
as pharyngitis and cellulitis to life-threatening necrotizing
fasciitis/myonecrosis and streptococcal toxic shock syndrome
(StrepTSS). Multiple extracellular toxins, alone and in com-
bination, are thought to mediate these infections, yet the
mechanisms of toxin regulation are not entirely established.
Methods: In the present study, a single insertion of transposon
Tn917 into the chromosome of a StrepTSS-associated M-type 3
strain of GAS altered the expression of many extracellular pro-
teins, including exotoxins known to be important in pathogenesis.
Results: Expression of the bicistronic gene speB/prsA in the
wild-type strain was not detectable during exponential growth
by northern analysis, but was dramatically activated in the
transposon mutant, suggesting that streptococcal pyrogenic ex-
otoxin B (SpeB) production in the transposon mutant was no
longer growth-phase dependent. Chromosomal localization stud-
ies demonstrated a single transposon insertion into an open
reading frame of a putative 248 amino acid protein, SpyM3_0606.
Complementation of the transposon mutant with a plasmid con-
taining SpyM3_0606 restored the wild-type toxin proﬁle.
Conclusion: This locus is unique to Streptococcus pyogenes and
is distinct from other known global toxin regulators such as CsrRS
and Mga. Due to its effects on extracellular toxins that are
important in pathogenesis, this gene has been designated vfr
for virulence factor related. An understanding of Vfr-mediated
toxin regulation may resolve unanswered questions regarding the
global toxin regulatory network in S. pyogenes.
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OL-025 Hepatitis B virus genotyping: comparison of two
type-speciﬁc primers PCR methods
Hui Jin*,1, Jie Wang1, Zhuo Li 2, Ling Yan1, Jingjing Nie1, Jie Li 1,
Hui Zhuang1. 1Department of Microbiology, Peking University
Health Science Center; 2Beijing You’an Hospital, Capital
University of Medical Sciences, Hepatitis Institute of Beijing
Municipal Health Bureau
Background: To compare and evaluate two type-speciﬁc primers
PCR genotyping methods of hepatitis B virus (HBV) which were
established by Naito et al (Naito method) and our lab (New
method).
Methods: The two genotyping methods were applied for detect-
ing the plasmids containing the HBV genomes of genotype A or D
or subgenotype B1 or C2 and the plasmids mixed with different
proportion of subgenotypes B1 and C2. In addition, the genotypes
of 113 serum samples of patients with chronic HBV infection were
identiﬁed by the two methods, respectively. The results were
veriﬁed by PCR products based sequencing.
Result: The sensitivity of the two methods showed no difference
when they were applied to detect the plasmids containing the
HBV genomes of genotype A or D or subgenotype B1 or C2.
While detecting the plasmids mixed with different proportion
of subgenotypes B1 and C2, the sensitivity of the New method
was superior than that of Naito method. Meanwhile, the speci-
ﬁcity of the New method was obviously superior than that of
Naito method. While detecting the serum samples, the total
discrepancy rate between the two methods was 16.8% (19/113).
Twelve of the 19 inconsistent genotypes by the two methods
were randomly selected and their PCR products were sequenced
directly. The sequencing results were identical with that of the
New methods.
Conclusion: The Newmethod is more sensitive, and its speciﬁcity
is superior to Naito method. It could be used for clinical and epi-
demiological studies on HBV genotype and subgenotype in China.
OL-026 Kinetics of interleukin-18 and HBV DNA during
IFN-therapy induced and spontaneous anti-HBeAg
seroconversion in patients with chronic
hepatitis B
Staffan Sylvan*,1,2, Ulla Hellstrom3,4. 1Dept. of Medical
Sciences, Uppsala University; 2Dept. of Communicable Disease
Control and Prevention, Uppsala County Council; 3Karolinska
Institute; 4Dept. of Communicable Disease Control and
Prevention, Stockholm County Council, Sweden
Background: Interleukin-18 (IL-18) is a Th1-type cytokine that
induce Interferon-gamma (IFN-γ) in T cells, natural killer (NK)
cells, B cells and dendritic cells. In addition IL-18 activates CD8+
T cells, which play a role in viral clearance. Furthermore, it has
been demonstrated that IL-18 inhibits hepatitis B virus replica-
tion in transgenic mice through the induction of IFN-γ. However,
no longitudinal studies to determine whether IL-18 regulation is
associated with viremia and to HBeAg seroconversion in patients
have yet been made.
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Methods: Levels of IL-18 was determined by ELISA in serum
from healthy individuals (n=31), HB-immune patients (n=13),
anti-HBe positive patients with HBV DNA levels below 104 (n=25)
or above 104 (n=20) copies/ml and HBeAg positive patients with
chronic hepatitis B (CHB) (n=14). HBV DNA was assessed by Cobas
Amplicor HBV Monitor TM test. IL-18 reactivity was monitored
longitudinally in comparison with the viremia in 15 CHB patients
treated with interferon-alpha.
Results: The serum levels of IL-18 was signiﬁcantly higher in anti-
HBeAg positive and HBeAg positive patients with CHB compared
with healthy individuals (p<0.05). In vivo, the longitudinal study
demonstrated a highly inverse correlation between the levels of
HBV DNA and the circulating concentrations of IL-18. Patients
with IFN alpha-induced reduction in HBV DNA levels exhibited
a signiﬁcant increase in measurable IL-18 reactivity (p<0.001)
which always peaked after the decrease of HBV DNA in serum.
Conclusions: The inverse correlation between the decrease of
HBV viremia and the increase of measurable circulatory levels
of IL-18 indicate a strong relationship between the control of
replication of HBV DNA and the production of IL-18 in CHB.
OL-027 The correlation of serum HBV DNA, HBeAg and
HBsAg contents in HBsAg-positive chronic
hepatitis B patients treated with interferon
Yao Xie*, Ming-hui Li, Li-jun Chen, Guo-hua Qiu, Yao Lu,
Dao-zhen. Xu. Department of Liver Diseases, Ditan Hospital,
Beijing, PR China
In HBeAg positive chronic hepatitis B treatment, serum HBeAg
loss or serological conversion was primary endpoint and the most
important parameter of the efﬁcacy evaluation. But in the pa-
tients treatment with interferon and nucleoside analogues, the
change modules of serum HBV DNA, HBeAg and HBsAg contents
was difference between the two kinds of drugs. The aim of this
study was analyzing the correlation ships among serum HBV DNA,
HBeAg and HBsAg contents in HBsAg-positive chronic hepatitis B
patients treated with interferon.
There were 228 cases of HBeAg-positive patients, with serum HB-
sAg positive for more than 6 months, HBV DNA content >5.0×105
copies/ml and ALT level from 41 to 400 U/ml, enrolled in
this study. After enrolled, patients was treated with PEGASYS,
180mg, subcutaneous injection once weekly, for 48 weeks, and
with another 24 week follow. The serum HBV NDA, HBeAg and
HBsAg contents were examined at 0, 24 and 48 week and the end
of follow.
The serum HBV NDA, HBeAg and HBsAg baseline were lg
7.139±0.974 copies/ml, lg 2.486±0.926 S/CO and lg 4.139±0.756
IU/ml, respectively, and the correlation among them were sig-
niﬁcance (p<0.001), and at 24, 48 week on-treatment and the
end of follow, the correlation among them was signiﬁcance
also (p<0.001). After mixed-variable linear regression analysis
tested, at 48 week, the HBsAg clear could be predicted by the
levels of HBsAg baseline and its descend extent at 24 week, and
HBV DNA descend extent at 24 and 48 week, and the HBeAg
clear could be predicted by the levels of HBeAg baseline and its
descend extent at 24 week, and HBV DNA descend extent at 24
and 48 week.
In this study it was shown that during the course of interferon
therapy, there were correlation among HBV DNA, HBeAg and HB-
sAg contents and their changes, and it was important monitoring
the changes of them.
OL-028 Therapeutic efﬁcacy of combination of
lamivudine with interferon-α for HBeAg positive
chronic hepatitis B: systematic review and
meta-analysis of randomized trials
Xin Sun*,1, Li Wang2, Giuseppe Barbaro3, Henry Chan4,
Gordon Guyatt1. 1Department of Clinical Epidemiology and
Biostatistics, McMaster University, Canada; 2Chinese Evidence-
Based Medicine Center, Sichuan University; 3Department of
Medical Pathophysiology, University La Sapienza, Italy;
4Department of Medicine and Therapeutics and Institute of
Digestive Disease, Chinese University of Hong Kong, Hong Kong
Backgroud: To assess effects of combination of lamivudine plus
interferon-α for HBeAg positive chronic hepatitis B.
Methods: We included randomized trials of combination of
interferon-α plus lamivudine vs. lamivudine or interferon-α alone
in adult patients with HBeAg positive chronic hepatitis B. We
searched MEDLINE, EMBASE, and Cochrane and SCI database
(1980-2008), supplemented with reference lists and contact with
trial investigators. We used random-effect model to pool trials,
and employed a limited number of pre-speciﬁed variables to
explore sources of heterogeneity.
Results: Compared to interferon-α, combination therapy did
not improve HBeAg seroconversion (29.3% vs. 28.3%; RR1.05,
95%CI0.81 to 1.35) and combined virological response (19.9% vs.
12.9%; 1.52, 0.82 to 2.86), loss of HBV DNA (38.1% vs. 31.1%;
1.38, 1.03 to 1.84), and ALT normalization (40.0% vs. 36.8%; 1.13,
0.93 to 1.38) at the end of post-treatment follow-up. Compared
to lamivudine, combination therapy improved HBeAg seroconver-
sion (30.5% vs. 17.8%; 1.76, 1.29 to 2.42), loss of HBV DNA (32.5%
vs. 19.8%; 1.61, 1.29 to 2.02), combined virological response
(25.1% vs. 10.8%; 2.30, 1.70 to 3.12), and ALT normalization
(37.9% vs. 24.8%; 1.52, 1.25 to 1.84) at the end of follow-up.
Combination therapy reduced resistance to lamivudine at the
end of treatment (7.2% vs. 25.5%; 0.28, 0.19 to 0.40).
Conclusions: Combination therapy improves treatment effects
over lamivudine, but has no superior effects over interferon-α.
Given increased costs and adverse events, combination therapy
of lamivudine plus interferon-α is not recommended for routine
use.
OL-029 Differential effects of interferon and lamivudine
on serum HBV RNA inhibition in patients with
chronic hepatitis B
Yi-Wen Huang*,1,2, Kazuaki Chayama3,4, Masataka Tsuge3,4,
Shoichi Takahashi 3,4, Tsuyoshi Hatakeyama3,4, Hiromi Abe3,4,
Michio Imamura3,4, Jui-Ting Hu1,5, Chun-Jen Liu2,6,
Ming-Yang Lai 2,6, Pei-Jer Chen2,6, Ding-Shinn Chen2,6,
Sien-Sing Yang1,5, Jia-Horng Kao2,6. 1Liver Unit, Cathay General
Hospital Medical Center, Taipei, Taiwan; 2Division of
Gastroenterology, Department of Internal Medicine, National
Taiwan University College of Medicine and National Taiwan
University Hospital, Taipei, Taiwan; 3Department of Medicine
and Molecular Science, Division of Frontier Medical Science,
Programs for Biomedical Research, Graduate School of
Biomedical Sciences, Hiroshima University, Hiroshima, Japan;
4Liver Research Project Center, Hiroshima University,
Hiroshima, Japan; 5Faculty of Medicine, Fu-Jen Catholic
University College of Medicine, Taipei, Taiwan; 6Graduate
Institute of Clinical Medicine, National Taiwan University
College of Medicine, Taipei, Taiwan
Background: Serum HBVRNA is detected during lamivudine ther-
apy, its pattern in sequential therapy of interferon and lamivu-
dine is unknown.
Methods: HBVDNA and RNA were quantiﬁed by reverse transcrip-
tion of HBV nucleic acid extract and real-time PCR in 10 patients
under lamivudine or entecavir, 6 under sequential interferon and
lamivudine, and 3 under short-term lamivudine.
